Conversations on Cancer: Transforming Patient Lives by Therapeutic and Regulatory Innovations, European Medicines Agency, Amsterdam, the Netherlands, from 1 February 2024, 15:30 (CET) to 1 February 2024, 17:00 (CET)

Submitted by Anonymous (not verified) on 15 January 2024 - 12:57

Conversations on Cancer: Transforming Patient Lives by Therapeutic and Regulatory Innovations, European Medicines Agency, Amsterdam, the Netherlands, from 1 February 2024, 15:30 (CET) to 1 February 2024, 17:00 (CET)

Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 15 January 2024 - 11:18

Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised

Annex to interim measures regarding notification of pharmacovigilance alerts by marketing authorisation holders under Regulation (EU) 2019/6: contact points

Submitted by Anonymous (not verified) on 12 January 2024 - 15:19

Annex to interim measures regarding notification of pharmacovigilance alerts by marketing authorisation holders under Regulation (EU) 2019/6: contact points

Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures

Submitted by Anonymous (not verified) on 12 January 2024 - 10:38

Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More